Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239030 | 0.83 | HSD17B10 (0.59) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL4529804 | 0.79 | BACE1 (0.51) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL28616399 | 0.77 | MAPT (0.49) | HSD17B10HPGDCA12CA2CA9 | |
| SCHEMBL13098114 | 0.76 | HSD17B10 (0.47) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL17595673 | 0.76 | GPR68 (0.49) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL4571036 | 0.76 | HSD17B10 (0.71) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL30464743 | 0.76 | HSD17B10 (0.71) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL18343871 | 0.76 | MEN1 (0.38) | HSD17B10KDM4EHPGDTSHRIDO1 | |
| SCHEMBL396451 | 0.75 | BACE1 (0.65) | BACE1HSD17B10KDM4EHPGDTSHR | |
| SCHEMBL29922357 | 0.75 | BACE1 (0.65) | BACE1HSD17B10KDM4EHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | RECQL, AR, DHX35 | BACE1 2445/4885HSD17B10 645/4885KDM4E 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.